A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 (INSPIRE-NF1)

May 18, 2026 updated by: Healx Limited

A Phase 2, Open-Label, Single Arm, Non-Controlled, Single-Stage Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Plexiform Neurofibroma and Neurofibromatosis Type 1

The trial will be an open label, single arm, phase 2 study to assess the tolerability and efficacy of HLX-1502 in participants with NF1 that are 16 years or older in age with progressive and/or symptomatic PN. This study will also investigate the safety and efficacy of HLX-1502 in a small cohort of 12 to 15 year olds.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

25

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35294
        • Recruiting
        • University of Alabama at Birmingham
        • Principal Investigator:
          • Girish Dhall
        • Contact:
        • Sub-Investigator:
          • Laura Katherine Metrock
    • California
      • Los Angeles, California, United States, 90027
        • Recruiting
        • Children's Hospital Los Angeles
        • Contact:
        • Principal Investigator:
          • Tena Rosser
        • Sub-Investigator:
          • Nathan Robison
        • Sub-Investigator:
          • Ashley Margol
        • Sub-Investigator:
          • Tom Davidson
        • Sub-Investigator:
          • Katrina O'Halloran
        • Sub-Investigator:
          • Sara-Jane Oneyeama
        • Sub-Investigator:
          • Anat Erdreich-Epstein
        • Sub-Investigator:
          • Kaaren Waters
        • Sub-Investigator:
          • Vless Trinidad
        • Sub-Investigator:
          • Kasey Rangan
      • Palo Alto, California, United States, 94304
        • Recruiting
        • Stanford University
        • Contact:
        • Principal Investigator:
          • Cynthia Campen
        • Sub-Investigator:
          • Sonia Partap
        • Sub-Investigator:
          • Paul Fisher
        • Sub-Investigator:
          • Katherine Ryan
    • Colorado
      • Aurora, Colorado, United States, 80045
        • Recruiting
        • Children's Hospital Colorado
        • Contact:
        • Principal Investigator:
          • Nicholas Foreman
        • Sub-Investigator:
          • Holly Lindsay
        • Sub-Investigator:
          • Shelby Winzent-Oonk
        • Sub-Investigator:
          • Molly Hemenway
    • District of Columbia
      • Washington D.C., District of Columbia, United States, 20010
        • Recruiting
        • Children's National Hospital
        • Sub-Investigator:
          • Roger Packer
        • Contact:
        • Principal Investigator:
          • Benjamin Siegel
        • Sub-Investigator:
          • Lindsay Kilburn
        • Sub-Investigator:
          • AeRang Kim
        • Sub-Investigator:
          • Amy Hont
        • Sub-Investigator:
          • Liny John
        • Sub-Investigator:
          • Brian Rood
        • Sub-Investigator:
          • Eugene Hwang
        • Sub-Investigator:
          • Holly Meany
    • Illinois
      • Chicago, Illinois, United States, 60637
        • Recruiting
        • University of Chicago
        • Contact:
        • Principal Investigator:
          • James Tonsgard
        • Sub-Investigator:
          • Shawn Damodharan
      • Chicago, Illinois, United States, 60611
        • Recruiting
        • Ann & Robert H. Lurie Children's Hospital of Chicago
        • Contact:
        • Principal Investigator:
          • Miriam Bornhorst
        • Sub-Investigator:
          • Angela Waanders
        • Sub-Investigator:
          • Ashley Plant
        • Sub-Investigator:
          • Alicia Lenzen
        • Sub-Investigator:
          • Maggie Seblani
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Recruiting
        • Indiana University
        • Contact:
        • Principal Investigator:
          • Steven Rhodes
        • Sub-Investigator:
          • Scott Coven
        • Sub-Investigator:
          • Jayne Vonbergen
        • Sub-Investigator:
          • Brian Weiss
        • Sub-Investigator:
          • Kathryn Nevel
    • Maryland
      • Baltimore, Maryland, United States, 21287
        • Recruiting
        • Johns Hopkins Hospital
        • Contact:
        • Principal Investigator:
          • Jaishri Blakeley
        • Sub-Investigator:
          • Shannon Langmead
        • Sub-Investigator:
          • Carlos Romo
        • Sub-Investigator:
          • Kelly Wypych
    • Missouri
      • St Louis, Missouri, United States, 63110
        • Recruiting
        • Washington University School of Medicine
        • Principal Investigator:
          • Amy Armstrong
        • Contact:
        • Sub-Investigator:
          • Angela Hirbe
        • Sub-Investigator:
          • Brian Van Tine
        • Sub-Investigator:
          • Mia Weiss
        • Sub-Investigator:
          • Mohamed Abdelbaki
        • Sub-Investigator:
          • Nicole Brossier
        • Sub-Investigator:
          • Andrew Cluster
        • Sub-Investigator:
          • Frederick Huang
        • Sub-Investigator:
          • Allison King
        • Sub-Investigator:
          • Bryan Sisk
        • Sub-Investigator:
          • Daniel Willis
        • Sub-Investigator:
          • David Wilson
        • Sub-Investigator:
          • Sanita Burgic
        • Sub-Investigator:
          • Linda Goldenberg
        • Sub-Investigator:
          • Loren Abernathy
        • Sub-Investigator:
          • Christina Carey
        • Sub-Investigator:
          • Leslie Glover
        • Sub-Investigator:
          • Ashley Meyer
        • Sub-Investigator:
          • Andrea Ogle
        • Sub-Investigator:
          • Camille Skaer
        • Sub-Investigator:
          • Molly Warner
    • New York
      • New York, New York, United States, 10016
        • Recruiting
        • New York University Langone Health
        • Contact:
        • Principal Investigator:
          • Kaleb Yohay
        • Sub-Investigator:
          • Jessica Clymer
        • Sub-Investigator:
          • Devorah Segal
        • Sub-Investigator:
          • Jordie Blum
    • Ohio
      • Cincinnati, Ohio, United States, 45229
        • Recruiting
        • Cincinnati Children's Hospital Medical Center
        • Contact:
        • Principal Investigator:
          • Peter De Blank
        • Sub-Investigator:
          • Erin Breese
        • Sub-Investigator:
          • Karen Burns
        • Sub-Investigator:
          • Ellen Chang
        • Sub-Investigator:
          • Richard Graham
        • Sub-Investigator:
          • Trent Hummel
        • Sub-Investigator:
          • LaQuita Jones
        • Sub-Investigator:
          • Lynn Lee
        • Sub-Investigator:
          • Benjamin Mizukawa
        • Sub-Investigator:
          • Aaron Mochizuki
        • Sub-Investigator:
          • Robin Norris
        • Sub-Investigator:
          • John Perentesis
        • Sub-Investigator:
          • Christine Phillips
        • Sub-Investigator:
          • Natasha Pillay-Smiley
        • Sub-Investigator:
          • Jonathan Bender
        • Sub-Investigator:
          • Thomas Galletta
        • Sub-Investigator:
          • Joseph Pressey
        • Sub-Investigator:
          • Lauren Pommert
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • Recruiting
        • Children's Hospital of Philadelphia
        • Contact:
        • Principal Investigator:
          • Michael Fisher
        • Sub-Investigator:
          • Jean Belasco
        • Sub-Investigator:
          • Stephanie Brosius
        • Sub-Investigator:
          • Kristina Cole
        • Sub-Investigator:
          • Jessica Foster
        • Sub-Investigator:
          • Cassie Kline
        • Sub-Investigator:
          • Chelsea Kotch
        • Sub-Investigator:
          • Jane Minturn
        • Sub-Investigator:
          • Amish Shah
    • Texas
      • Dallas, Texas, United States, 75390
        • Recruiting
        • University of Texas Southwestern Medical Center
        • Contact:
        • Principal Investigator:
          • Laura Klesse
        • Sub-Investigator:
          • Justin Jordan
        • Sub-Investigator:
          • Michael Youssef
        • Sub-Investigator:
          • Evan Noch
        • Sub-Investigator:
          • Elizabeth Maher
        • Sub-Investigator:
          • Daniel Bowers
        • Sub-Investigator:
          • Jonathan Wickiser
        • Sub-Investigator:
          • Alexis Kennedy
        • Sub-Investigator:
          • Devon Knotts

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. All participants must have a diagnosis of NF1 based on the 2021 revised consensus criteria.
  2. Participants must have PN(s) that are progressive OR are causing significant morbidity, such as (but not limited to) head and neck lesions that are compromising the airway or great vessels, brachial or lumbar plexus lesions that are causing nerve compression and loss of function, lesions causing significant disfigurement (e.g., orbital lesions), lesions of the extremity that cause limb hypertrophy or loss of function, and painful lesions. Participants with paraspinal PN will be eligible for this trial. Histologic confirmation of tumor is not necessary but should be considered if there are clinical or radiographic findings concerning for malignant transformation of a PN.
  3. Measurable Disease: Participants must have measurable PN(s) amenable to volumetric MRI analysis. For the purpose of this study, the target lesion must be seen on at least 3 consecutive MRI slices and the field of view must contain the entire tumor of interest. Tumors must be at least 3 mL in volume (most PN 3 cm in longest diameter will meet this criteria). If the tumor is < 3 cm in longest diameter, the participant may still be eligible. Central review of the MRI of the target PN is required prior to enrollment to ensure that the tumor is measurable and amenable to volumetric analysis.
  4. Age: Participants must be ≥ 12 years of age at the time of study entry. Note: Although prior MEKi therapy is not a requirement, patients should be counseled on the availability of FDA-approved MEKi therapies prior to enrollment.
  5. Weight ≥ 42 kg.
  6. Performance Level: Participants must have a Lansky (12-15 years of age) or Karnofsky (16+ years of age) score ≥ 50%.
  7. Organ Function Requirements: Adequate Bone Marrow Function, Adequate Renal Function, Adequate Liver Function, Normal pancreatic function: amylase and lipase levels ≤ 1.5 x ULN. Blood pressure within upper limit of normal as defined below based on the average of the 2nd and 3rd of a total of 3 consecutive measurements, 5 minutes apart. Antihypertensives are permissible to achieve blood pressure within ULN, however must be on stable antihypertensive regimen with no adjustments within 14 days of enrollment.
  8. Sexually active women of childbearing potential and fertile male participants and their partners must agree to use effective methods of contraception e.g., hormonal oral contraception, injectables, intrauterine device, surgical sterilization including vasectomy, or hormonal implant with barrier methods (male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment. Barrier methods alone are insufficient. True sexual abstinence or evidence of surgical sterility (e.g. vasectomized partner, post-hysterectomy, menopause with last menstrual period >=12 months prior to screening visit) are acceptable method of birth control. Persons of childbearing potential will be given a pregnancy test within 14 days prior to first dose of study treatment and must have a negative urine or serum pregnancy test.
  9. The participant is not planning to undergo surgery or other interventions/ treatments for the target lesion, except protocol specified therapy, for the duration of the study.
  10. The participant or the participant's legal authorized representative is able to understand the informed consent form describing the risks of the study and voluntarily signs the informed consent document.
  11. In the opinion of the investigator, the participant is willing and able to attend study visits, comply with the study procedures as specified in the protocol, and comply with the administration of the study drug.

Exclusion Criteria:

  1. Prior treatment with HLX-1502 for a PN.
  2. The participant has used any of the following systemic medications/ therapies within the specified period prior to enrollment: MEK-inhibitors, other drugs in the TKI class, HLX-1502, Participants may have received treatment for a PN or other tumor/malignancy but must have fully recovered to baseline or CTCAE ≤ Grade 1 from acute toxicities from prior therapies except alopecia, Myelosuppressive chemotherapy, Hematopoietic growth factors, Biologic (anti-neoplastic agent), Investigational Drugs, Any other systemically administered anti-neoplastic agent and Radiation therapy.
  3. Evidence of an NF1-related tumor such as optic pathway or other low-grade glioma, high-grade glioma, malignant peripheral nerve sheath tumor, or other cancer/tumor requiring treatment with chemotherapy, biologic therapy, surgery or radiation therapy.
  4. Participants with high-grade glioma, malignant peripheral nerve sheath tumor, or other malignancy who received treatment in the last 12 months. Exceptions include basal cell carcinoma of the skin and squamous cell carcinoma of the skin that have undergone potentially curative therapy. If the investigator has any clinical concerns for ANNUBP/Atypical Neurofibroma or MPNST, a biopsy sample must be taken prior to study confirming eligibility.
  5. Dental braces or prosthesis that interfere with volumetric analysis of the neurofibroma(s).
  6. Surgery: Any major surgery within 12 weeks before starting the Treatment Period or foreseen during participation in the trial, any minor surgeries within 1 month before first dose of study treatment and Participants must have complete wound healing from major surgery or minor surgery before the first dose of study treatment. Participants with clinically relevant ongoing complications from prior surgery are not eligible.
  7. Cataracts noted on ophthalmologic exam.
  8. Cardiovascular disorders.
  9. Other clinically significant disorders that would preclude safe study participation, including active infection, a known history of HIV seropositivity or known immunodeficiency or Known history of Hepatitis B or Hepatitis C.
  10. Participants who require treatment with a drug that is a substrate of CYP1A2, CYP2C8, UGT1A1, UGT1A3 with a narrow therapeutic index during protocol therapy.
  11. Known severe sensitivity to HLX-1502 or any excipient of HLX-1502 or history of allergic reactions attributed to compounds of similar chemical or biologic composition to HLX-1502.
  12. Known severe sensitivity to FD&C Yellow No. 5.
  13. Participants receiving therapeutic anticoagulation with vitamin K antagonist.
  14. Participants presently with iron deficiency and/or actively receiving iron replacement or requiring treatment with copper or zinc for any indication at study baseline.
  15. Pregnant or breast-feeding women.
  16. Unable or unwilling to swallow tablets.
  17. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter ingestion and/or the absorption of HLX-1502.
  18. Participants who have other medical, social or concurrent challenges that are likely to negatively impact their ability to meet all of the trial obligations and therefore may increase the risk of safe participation in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: HLX-1502
Participants will take an oral dose three times a day (with or without food) for 12 cycles. A cycle is defined as 28 days. Participants with a partial response or stable disease with a previously progressive tumor and/or clinical improvement can continue therapy for an additional 12 cycles for a total of 24 cycles.
Drug: HLX-1502
Participants will take an oral dose three times a day (with or without food) for up to 24 cycles (a cycle is defined as 28 days).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PN response rate
Time Frame: 12 months
Response will be determined by a blinded centralized review of volumetric MRI. A partial response (PR) is defined as ≥ 20% decrease in the volume of target PN.
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Duration of response (DOR) and Time to response (TOR)
Time Frame: 12 months
Response will be determined by a blinded centralized review of volumetric MRI.
12 months
Safety and tolerability of HLX-1502
Time Frame: 12 months
Adverse events (AEs) will be assessed according to toxicities graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
12 months
PN response rate
Time Frame: 24 months
Response will be determined by a blinded centralized review of volumetric MRI. A partial response (PR) is defined as ≥ 20% decrease in the volume of target PN.
24 months
Pharmacokinetics of HLX-1502
Time Frame: 12 months
Measured by plasma concentrations
12 months
Confirmed PN response rate
Time Frame: 12 and 24 months
Confirmed response will be determined by a blinded centralized review of volumetric MRI
12 and 24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Healx Limited

Investigators

  • Study Chair: Miriam Bornhorst, Lurie's Children's Hospital
  • Study Chair: Michael Fisher, Children's Hospital of Philadelphia
  • Study Chair: Kathryn Nevel, Indiana University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 10, 2025

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

January 1, 2028

Study Registration Dates

First Submitted

July 30, 2024

First Submitted That Met QC Criteria

August 2, 2024

First Posted (Actual)

August 7, 2024

Study Record Updates

Last Update Posted (Actual)

May 19, 2026

Last Update Submitted That Met QC Criteria

May 18, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HLX015-0201

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neurofibromatosis Type 1

Clinical Trials on HLX-1502

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe